Mid-Illinois Hematology Oncology Associates Limited

Normal, Illinois 61761

0 studies enrolling now · 7 studies all time

What they study most

Breast Adenocarcinoma, Breast Cancer, Breast Ductal Carcinoma In Situ, Hormone Receptor Positive, Invasive Breast Carcinoma, Melanoma of Unknown Primary, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma, Recurrent Melanoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IB Lung Non-Small Cell Carcinoma AJCC v7

Studies at this site

• Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer — Running, not enrolling
• Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery — Running, not enrolling
• Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) — Running, not enrolling
• Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery — Completed
• Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer — Running, not enrolling
• Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy — Completed
• S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer — Completed